An American biotechnology company, Moderna Inc (Nasdaq:MRNA) disclosed that the Company speed up its efforts to develop COVID-19 vaccine for combating the pandemic.
After the FDA approval for Phase 2 clinical trials, Moderna plans to commence Phase 2 clinical trials for its COVID-19 vaccine shortly while Phase 3 clinical trials are probable to begin in upcoming months.
Shares of Moderna jumped 8% to close the day’s trade at USD 53.19 on 7 May 2020.